Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03700229
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT03695744
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 395
- Registration Number
- NCT03652064
- Locations
- 🇺🇸
Cancer And Hematology Centers of Western Michigan PC, Grand Rapids, Michigan, United States
🇺🇸Saint Lukes Hospital Saint Lukes Cancer Specialists, Kansas City, Missouri, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Interventions
- Drug: BortezomibDrug: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: MyocetDrug: DoxorubicinDrug: 6-MercaptopurineDrug: EtoposideDrug: Fludarabine PhosphateDrug: PrednisoloneDrug: IfosfamideDrug: TioguaninDrug: PegaspargaseDrug: MethotrexateDrug: ErwinaseDrug: VincristineDrug: Vindesine
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03641456
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT03617484
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
- Conditions
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 662
- Registration Number
- NCT03617731
- Locations
- 🇩🇪
Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bad Saarow, Germany
🇩🇪Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany
🇩🇪Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie, Darmstadt, Germany
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Leaf Vertical Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03607643
- Locations
- 🇺🇸
Southwest Cancer Center, Orlando, Florida, United States
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03591744
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.